Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Drugs Made In America Acquisition IIDMII 14 3-Year EPS without NRI Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates DMII with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 159 Diversified Financial Services companies, Drugs Made In America Acquisition II ranks worse than 628930.19% on this metric.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
Drugs Made In America Acquisition II (NAS:DMII) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Drugs Made In America Acquisition II 3-Year EPS without NRI Growth Rate Related Terms
DMII vs EVAC, CXII, BCSS: 3-Year EPS without NRI Growth Rate Comparison
For the Shell Companies subindustry, Drugs Made In America Acquisition II's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Drugs Made In America Acquisition II 3-Year EPS without NRI Growth Rate vs Diversified Financial Services Industry
For the Diversified Financial Services industry and Financial Services sector, Drugs Made In America Acquisition II's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Drugs Made In America Acquisition II's 3-Year EPS without NRI Growth Rate falls into.
Drugs Made In America Acquisition II 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 0.00% mean?
Drugs Made In America Acquisition II (DMII) has a 3-Year EPS without NRI Growth Rate of 0.00% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Drugs Made In America Acquisition II and its competitors. According to the industry distribution chart, Drugs Made In America Acquisition II ranks #999999 out of 159 companies in the Diversified Financial Services industry.
Is Drugs Made In America Acquisition II's 3-Year EPS without NRI Growth Rate too high?
Drugs Made In America Acquisition II's current 3-Year EPS without NRI Growth Rate is 0.00%. Based on the distribution chart, Drugs Made In America Acquisition II ranks #999999 out of 159 companies in the Diversified Financial Services industry, which is in the bottom quartile relative to peers. Overall, Drugs Made In America Acquisition II has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Drugs Made In America Acquisition II's 3-Year EPS without NRI Growth Rate compare to EVAC and CXII?
According to the Diversified Financial Services industry distribution chart, Drugs Made In America Acquisition II ranks #999999 out of 159 companies for 3-Year EPS without NRI Growth Rate. This places Drugs Made In America Acquisition II in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Diversified Financial Services company?
The median 3-Year EPS without NRI Growth Rate among Diversified Financial Services companies is 16.00, based on 159 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Drugs Made In America Acquisition II and its competitors. For the Diversified Financial Services industry, the median 3-Year EPS without NRI Growth Rate is 16.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Drugs Made In America Acquisition II's current 3-Year EPS without NRI Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Drugs Made In America Acquisition II stock overvalued right now?
Drugs Made In America Acquisition II (DMII) has a current 3-Year EPS without NRI Growth Rate of 0.00%. The current 3-Year EPS without NRI Growth Rate is 0.00%. Drugs Made In America Acquisition II's overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Drugs Made In America Acquisition II (DMII), the current 3-Year EPS without NRI Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DMII has been successfully added to your 
